by Junod Moser D, Boulet P, Childs M, Shieh M, Pécoul B. Journal of Intellectual Property Law & Practice 2023, jpad025. doi: doi.org/10.1093/jiplp/jpad025
Summary: There is growing policy interest in public returns on public investments and ensuring that investments in pharmaceutical research and development result in innovation and equitable access. One approach is to include conditions in research and development agreements, but there are few publicly available examples. The authors of this paper share DNDi’s collaboration agreement templates, providing examples of an approach to achieving the balance of various interrelated provisions on ownership of the research, cross-licensing rights, affordability of the final products, termination rights and technology transfer. DNDi has devised an approach to intellectual property in its collaboration agreements that aims to develop treatments as public goods. The templates reflect DNDi and its partners’ objective of delivering affordable treatments to neglected populations.
